摘要
目的观察替格瑞洛与氯吡咯雷治疗急性冠脉综合征(ACS)合并糖尿病患者的临床效果。方法选取于2017年6月~2018年3月来我院就诊的100例ACS合并糖尿病患者作为研究对象,采用随机数字表法将其分为观察组(替格瑞洛组)和对照组(氯吡咯雷组),每组各50例。所有患者均接受阿司匹林肠溶片基础治疗,观察组患者在常规治疗的基础上使用替格瑞洛片进行治疗,对照组患者在常规治疗基础上使用硫酸氢氯吡格雷片进行治疗。随访1年,比较两组患者的主要不良心血管事件(MACE)总发生率及不良反应总发生率。结果观察组的MACE总发生率低于对照组,差异有统计学意义(P<0.05);两组患者的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论替格瑞洛治疗ACS合并糖尿病的不良反应发生情况与氯吡格雷基本相近,而MACE发生率低,在预防心血管不良事件方面,替格瑞洛比氯吡格雷更有效,具有推广使用价值。
Objective To observe the clinical effect of Tiglillo and Clopidogrel in the treatment of acute coronary syndrome (ACS) with diabetes mellitus. Methods A total of 100 patients with ACS and diabetes mellitus hospitalized in our hospital from June 2017 to March 2018 were selected as study objects. According to the random number table method, they were divided into observation group (Tigrillo group) and control group (Clopidogrel group), 50 cases in each group. All patients received basic treatment of Aspirin Enteric-coated Tablets. Patients in observation group were treated with Tegrilol Tablets on the basis of routine treatment, while patients in the control group were treated with Clopidogrel Tablets on the basis of routine treatment. The total incidence of major adverse cardiovascular events (MACE) and adverse reactions were compared between the two groups after 1 year follow-up. Results Compared with the control group, the total incidence of MACE in the observation group was lower, the difference was statistically significant (P<0.05). There was no statistically significant difference in the total incidence of adverse reactions between the two groups (P>0.05). Conclusion Tiglilo and Clopidogrel are similar in adverse reactions, but the incidence of MACE is lower. Tiglilo is more effective than Clopidogrel in the prevention of cardiovascular adverse events and has the value of popularization and application.
作者
林斌
黄志华
LIN Bin;HUANG Zhi-hua(Department of First Internal Medicine,Meizhou Hospital of Traditional Chinese Medicine,Guangdong Province,Meizhou 514071,China)
出处
《中国当代医药》
2019年第19期28-31,共4页
China Modern Medicine
基金
广东省梅州市医药卫生科研立项课题(2017-B-29)
